Sergio Quezada

Fondateur chez ACHILLES THERAPEUTICS PLC

Fortune : 304 204 $ au 30/06/2024

49 ans

Consumer Services

Health Technology

Profil

Sergio Quezada is the founder of Achilles Therapeutics UK Ltd.
(founded in 2016) and Achilles Therapeutics Plc (founded in 2020), where he holds the title of Chief Scientific Officer.
He is currently a Professor-Cancer Institute at University College London since 2011.
Dr. Quezada obtained his undergraduate degree from Pontificia Universidad Católica de Chile and his doctorate from Dartmouth Medical School.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
ACHILLES THERAPEUTICS PLC 0,92%	01/02/2023	373 257 ( 0,92% )	304 204 $	30/06/2024

Postes actifs de Sergio Quezada

Sociétés	Poste	Début
ACHILLES THERAPEUTICS PLC	Fondateur	01/11/2020
University College London	Corporate Officer/Principal	01/01/2011

Tous les postes actifs de Sergio Quezada

Anciens postes connus de Sergio Quezada

Sociétés	Poste	Fin
Achilles Therapeutics UK Ltd. Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.	Fondateur	-